Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7673396 alone and in combination with other anticancer drugs in RAS-mutant advanced solid tumors
NL-OMON59682Phase 1Recruiting
- Sponsor
- Roche
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RG6505 in Nonhematologic neoplasms (2 arms), sponsored by Roche. Started Aug 2026; status: recruiting.
02
Drugs
RG6505
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59682.